Suppr超能文献

碳酸氢钠加乙酰半胱氨酸预防原发性和挽救性经皮冠状动脉介入治疗中的对比剂肾病:BINARIO(急性心肌梗死中的碳酸氢盐和 N-乙酰半胱氨酸)研究。

Sodium bicarbonate plus N-acetylcysteine to prevent contrast-induced nephropathy in primary and rescue percutaneous coronary interventions: the BINARIO (BIcarbonato e N-Acetil-cisteina nell'infaRto mIocardico acutO) study.

机构信息

Department of Cardiovascular Medicine and Center of Hemodialysis, Catholic University of the Sacred Heart, 00168 Rome, Italy.

出版信息

EuroIntervention. 2012 Nov 22;8(7):839-47. doi: 10.4244/EIJV8I7A127.

Abstract

AIMS

Contrast-induced nephropathy (CIN) is a frequent and potentially harmful complication of percutaneous coronary interventions (PCI), especially in the setting of ST-elevation myocardial infarction (STEMI). We tested the efficacy of a sodium bicarbonate (SB)-based hydration in urgent PCI for STEMI.

METHODS AND RESULTS

From June 2009 to September 2010, 262 consecutive STEMI patients undergoing urgent PCI were prospectively enrolled and treated by SB-based hydration (154 mEq/L at 3 ml Kg-1 for one hour followed by 1 ml Kg-1 for six hours) (group A). As controls, 262 consecutive STEMI patients receiving 0.9% saline hydration (1 ml Kg-1 for 24 hours) before June 2009 were retrospectively enrolled (group B). Both groups received high-dose N-acetylcysteine (NAC). The primary endpoint was the composite of in-hospital death, need for dialysis and CIN (≥25% increase in serum creatinine at 48 hours). The two groups were comparable for baseline clinical and procedural characteristics, for Mehran risk score and baseline estimated glomerular filtration rate. The primary combined endpoint was significantly reduced in group A as compared to group B (9.2 vs. 18.7%, p=0.023) with a number needed to treat (NNT) of 11. Specifically, a significant reduction of both in-hospital death (2.3 vs. 6.1%, p=0.049, NNT 27) and CIN (8.0 vs. 14.1%, p=0.03, NNT 17) was observed, with no difference in the need for dialysis.

CONCLUSIONS

Our data indicate that hydration with sodium bicarbonate in addition to high-dose NAC in the setting of urgent PCI for STEMI is associated with a net clinical benefit.

摘要

目的

对比剂肾病(CIN)是经皮冠状动脉介入治疗(PCI)的常见且潜在有害的并发症,特别是在 ST 段抬高型心肌梗死(STEMI)的情况下。我们测试了在 STEMI 患者行紧急 PCI 时使用碳酸氢钠(SB)水化的疗效。

方法和结果

从 2009 年 6 月到 2010 年 9 月,前瞻性纳入了 262 例连续的行紧急 PCI 的 STEMI 患者,并接受 SB 水化治疗(1 小时内给予 3 ml/kg 的 154 mEq/L 碳酸氢钠,随后 6 小时内给予 1 ml/kg)(A 组)。作为对照,回顾性纳入了 2009 年 6 月前接受 0.9%生理盐水水化(24 小时内给予 1 ml/kg)的 262 例连续的 STEMI 患者(B 组)。两组均给予大剂量 N-乙酰半胱氨酸(NAC)。主要终点是住院期间死亡、需要透析和 CIN(48 小时时血清肌酐增加≥25%)的复合终点。两组在基线临床和手术特征、Mehran 风险评分和基线估计肾小球滤过率方面相似。与 B 组相比,A 组的主要复合终点明显降低(9.2% vs. 18.7%,p=0.023),治疗需要数(NNT)为 11。具体而言,观察到住院期间死亡(2.3% vs. 6.1%,p=0.049,NNT 27)和 CIN(8.0% vs. 14.1%,p=0.03,NNT 17)的发生率均显著降低,透析的需求无差异。

结论

我们的数据表明,在 STEMI 患者行紧急 PCI 时,除了给予大剂量 NAC 之外,使用碳酸氢钠水化可带来净临床获益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验